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whereas in the small cell lung cancer group 6 out of the total of 17 
(35.29%) developed brain metastases. The development of brain 
metastases in non small cell lung cancer was however independent of 
the initial stage of the disease, primary treatment received and the time 
elapsed between diagnosis and treatment.
Conclusion: PCI is recommended treatment for limited disease SCLC 
patients. Despite the observed phenomenon of potentially increasing 
numbers of patients with relapse in the brain as a ‘sanctuary site’, our 
data almost concurs with national ﬁgures suggesting that brain metas-
tases are three times more common in SCLC compared to NSCLC. We 
did not ﬁnd any risk factors that predicted development of brain me-
tastases in patients receiving radical treatment. In the case of NSCLC, 
this review highlights that brain metastases occurred independently of 
disease stage and response to treatment, making it difﬁcult to individu-
alise patients who would beneﬁt from PCI. We therefore feel that the 
current practice of not giving PCI to patients with Non small cell lung 
cancer is the best approach
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Background: Approximately 1 in 4 patients with NSCLC will develop 
brain metastases. For many years the standard therapy for patients with 
inoperable brain metastases has remained a combination of steroids 
and whole brain radiotherapy (WBRT). However, WBRT causes side 
effects and has never been shown to correlate with an improved quality 
or length of survival. In view of the fact that the median survival from 
diagnosis of brain metastases is only approximately 3 months, a large 
randomised trial is required to determine whether WBRT provides 
improved survival, function and/or enhances quality of life for these 
patients.
Methods: The QUARTz trial will compare Optimal Supportive Care 
(OSC, including dexamethasone) with OSC (including dexamethasone) 
and WBRT (20Gy in 5f) in the treatment of patients with inoperable 
brain metastases from NSCLC. The trial has been designed to be very 
pragmatic. Thus if a clinician is certain that WBRT will or will not be 
of beneﬁt for a speciﬁc patient, QUARTz should not be considered. 
However, if the clinician is uncertain that WBRT is the way forward, 
QUARTz is an opportunity to address that uncertainty. The primary 
endpoint will be quality adjusted life years (QALYs), the aim of which 
is to combine duration and quality of life in one measure. As many 
of these patients will be too ill to travel to hospital on a regular basis, 
information on each patient’s well-being will be collected via a weekly 
telephone assessment. A questionnaire including the EQ-5D and a list 
of symptoms will be used. Data from the EQ-5D will be combined with 
duration of survival to calculate each patient’s QALY. QUARTz has 
been designed as a non-inferiority trial on the basis that a >20% relative 
decrease in QALYs with OSC alone would be clinically unacceptable. 
Therefore a total of at least 1000 patients will be required to reliably 
exclude such a difference (80% power, 1-sided alpha of p=0.025). 
The effect of terminal cancer on patients’ carers is an under-researched 
area. The QUARTz trial will attempt to address this issue, by also 
collecting information on carers concerns via a weekly telephone call 
using the Carer Concerns Checklist.
Conclusions: QUARTz will produce robust evidence for the inclu-
sion or otherwise of WBRT in the routine management of patients 
with NSCLC and non-resectable brain metastases. Furthermore this 
large, pragmatic, international trial may lead to developments in other 
disease areas, as approximately 20-40% of all cancer patients develop 
brain metastases. The trial is now actively recruiting in the UK (MRC), 
Australia and New Zealand (TROG), and discussions with other groups 
are ongoing. 
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The Nordic experience with SBRT for medically inoperable stage I 
NSCLC, based on a retrospective analysis of 138 inoperable patients 
treated during 1996-2003, showed an impressing overall response rate 
(CR, PR) of 61%, a local control rate of 88%, and the 3- and 5-year 
overall survival was 52 and 26% respectively. The lung cancer speciﬁc 
3- and 5-year overall survival was 66 and 40% respectively (Baumann 
P. et al. Acta Oncol. 2006;45(7):787-95). We have now performed a 
GCP controlled phase II study on the same category of pats.(60 cases 
from 7 different centres in Sweden, Norway and Denmark) with inclu-
sion Aug.2003 - Sept.2005. Median age was 76 years (range 58-87 y) 
with 28 males and 32 women. Mean FEV1 at start was 59 %. Mean 
karnofsky index before treatment was 82. Sixty-ﬁve % were T1 and 
35% T2 tumors. Mean tumor diam. was 25 mm (6-49). Mean tumors 
vol. was 16 cc (1-51). The tumours were morphologically veriﬁed in 
70% of the cases, 17% squamous cell carcinoma, 33% adenocarcinoma 
and 20% unspeciﬁed NSCLC. The patients were considered inoperable 
mainly because of COPD or CVD. Four patients refused surgery.
Treatment: SBRT was delivered after immobilizing the patients in a 
stereotactic body frame (SBF). A 3D conformal multiﬁeld technique 
was used. The patients were treated with a dose of 15 Gy x 3 (BED 112 
Gy) with the 65% isodose to the periphery of the PTV. Mean volumes 
of GTV and PTV were 17 cc and 72 cc, and the mean dose to GTV was 
65 Gy. To the ipsilateral lung, excluding the GTV, the mean dose was 
7.4 Gy. All patients were planned with pencil beam algorithms in the 
Helax-TMS or Eclipse systems, which both overestimate the dose in 
the volume between the GTV and PTV. Data from Monte-Carlo simula-
